Skip to main content

Search

Our response to COVID-19

Our response to COVID-19
Mar 24, 2020Yes

Johnson & Johnson, as the world’s largest and most broadly-based healthcare company, has mobilised its resources, including expediting the development and production of a vaccine, in response to COVID-19. Information on our response is available at www.jnj.com/coronavirus.  

Medicine supply in Australia

Janssen continues to supply its medicines in Australia and there are no disruptions due to COVID-19. 

Employees visiting healthcare facilities and interactions with healthcare professionals 

We are prioritising the interests of our patients and healthcare professionals at this time and we will do what we can to minimise the spread of infection, and the impact on those most vulnerable. Recognising that a significant proportion of the patients we serve are immuno-compromised, we are suspending visits to hospitals and clinics until at least 17 April 2020.  

Operation of the Janssen Australia business 

To make sure that Janssen Australia can continue to serve our patients, healthcare professionals and the community, we have changed some aspects of the way we operate. In addition to suspending visits to hospitals and clinics, we have also undertaken the following measures: 

  • All employees who can meet their job responsibilities by working from home will do so until at least Friday 17 April 2020. 

  • We will support meetings with healthcare professionals and facilities through virtual platforms rather than in person. Any planned conferences will be deferred or take place supported by virtual platforms.  

Contacting Janssen  

As a leader in global health, our top priority remains our patients, customers and employees.   

We remain available via our normal channels: https://www.janssen.com/australia/contact-us  

Government information and resources on COVID-19 

 

 

As a leader in global health, our top priority remains our patients, customers and employees.